{"id":"https://openalex.org/W28790285","doi":"https://doi.org/10.1176/ajp.152.1.122","title":"Fluoxetine and extrapyramidal side effects","display_name":"Fluoxetine and extrapyramidal side effects","alternate_titles":[],"publication_year":1995,"publication_date":"1995-01-01","ids":{"openalex":"https://openalex.org/W28790285","doi":"https://doi.org/10.1176/ajp.152.1.122","mag":"28790285","pmid":"https://pubmed.ncbi.nlm.nih.gov/7802102"},"language":"en","primary_location":{"id":"doi:10.1176/ajp.152.1.122","doi":"https://doi.org/10.1176/ajp.152.1.122","is_oa":false,"landing_page_url":"https://doi.org/10.1176/ajp.152.1.122","pdf_url":null,"source":{"id":"https://openalex.org/S116025658","display_name":"American Journal of Psychiatry","issn_l":"0002-953X","issn":["0002-953X","1535-7228"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316602","host_organization_name":"American Psychiatric Association","host_organization_lineage":["https://openalex.org/P4310316602"],"host_organization_lineage_names":["American Psychiatric Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Psychiatry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W28790285"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109153021","display_name":"David Morris Coulter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I80281795","display_name":"University of Otago","ror":"https://ror.org/01jmxt844","country_code":"NZ","type":"education","lineage":["https://openalex.org/I80281795"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"D M Coulter","raw_affiliation_strings":["University of Otago Medical School, Dunedin, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Otago Medical School, Dunedin, New Zealand","institution_ids":["https://openalex.org/I80281795"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079570250","display_name":"Peter Ian Pillans","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P I Pillans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":43.6088,"has_fulltext":false,"cited_by_count":180,"citation_normalized_percentile":{"value":1.0,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"152","issue":"1","first_page":"122","last_page":"125"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0794999971985817,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":1.0},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.9800000190734863},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.9829999804496765},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.3889999985694885},{"id":"https://openalex.org/keywords/psychotropic-drugs","display_name":"psychotropic drugs","score":0.5910000205039978},{"id":"https://openalex.org/keywords/dopamine-receptor-antagonists","display_name":"dopamine antagonists","score":0.7749999761581421},{"id":"https://openalex.org/keywords/lithium","display_name":"lithium","score":0.5619999766349792},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8920000195503235},{"id":"https://openalex.org/keywords/tricyclic-antidepressants","display_name":"tricyclic antidepressants","score":0.9660000205039978},{"id":"https://openalex.org/keywords/metoclopramide","display_name":"metoclopramide","score":0.9599999785423279}],"concepts":[{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.890882134437561},{"id":"https://openalex.org/C2777393122","wikidata":"https://www.wikidata.org/wiki/Q416417","display_name":"Akathisia","level":4,"score":0.528908371925354},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4004722833633423},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3365492820739746},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.25932687520980835},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1778111457824707},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.1294814646244049},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.07815977931022644},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.06405079364776611},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000929","descriptor_name":"Antidepressive Agents, Tricyclic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001480","descriptor_name":"Basal Ganglia Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D001480","descriptor_name":"Basal Ganglia Diseases","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008094","descriptor_name":"Lithium","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009520","descriptor_name":"New Zealand","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1176/ajp.152.1.122","doi":"https://doi.org/10.1176/ajp.152.1.122","is_oa":false,"landing_page_url":"https://doi.org/10.1176/ajp.152.1.122","pdf_url":null,"source":{"id":"https://openalex.org/S116025658","display_name":"American Journal of Psychiatry","issn_l":"0002-953X","issn":["0002-953X","1535-7228"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316602","host_organization_name":"American Psychiatric Association","host_organization_lineage":["https://openalex.org/P4310316602"],"host_organization_lineage_names":["American Psychiatric Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Psychiatry","raw_type":"journal-article"},{"id":"pmid:7802102","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7802102","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The American journal of psychiatry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1964525922","https://openalex.org/W1980782502","https://openalex.org/W1989651461","https://openalex.org/W1990982116","https://openalex.org/W2011582509","https://openalex.org/W2013553174","https://openalex.org/W2020944051","https://openalex.org/W2024347494","https://openalex.org/W2051686756","https://openalex.org/W2054139040","https://openalex.org/W2069566385","https://openalex.org/W2095081297","https://openalex.org/W2272930841","https://openalex.org/W2338929165","https://openalex.org/W2341195774","https://openalex.org/W2395889083","https://openalex.org/W2397912057","https://openalex.org/W2407080477","https://openalex.org/W2410250385","https://openalex.org/W2413266168","https://openalex.org/W2474347580","https://openalex.org/W2479189631","https://openalex.org/W2619989631","https://openalex.org/W4212874028"],"related_works":["https://openalex.org/W2428918256","https://openalex.org/W2409554297","https://openalex.org/W2470754838","https://openalex.org/W2161212164","https://openalex.org/W2054139040","https://openalex.org/W2389520961","https://openalex.org/W2097365507","https://openalex.org/W3175799566","https://openalex.org/W1989651461"],"abstract_inverted_index":{"OBJECTIVE:":[0],"The":[1,121],"authors'":[2],"goal":[3],"was":[4,88,117],"to":[5,58],"determine":[6],"whether":[7,51],"fluoxetine":[8,26,44,70,125,136,139],"is":[9],"associated":[10,42,128],"with":[11,43,129,135],"extrapyramidal":[12,21,79,130],"side":[13],"effects.":[14],"METHOD:":[15],"They":[16],"assessed":[17],"the":[18,28,89,97,142],"notifications":[19,77],"of":[20,63,78,96],"manifestations":[22],"in":[23,27,66,144],"patients":[24,68,101,145],"given":[25,69],"New":[29,72],"Zealand":[30],"Intensive":[31],"Medicines":[32],"Monitoring":[33],"Programme,":[34],"a":[35,46],"national":[36],"system":[37],"that":[38,124],"monitored":[39],"adverse":[40,53,64],"reactions":[41,54,65],"over":[45],"4-year":[47],"period,":[48],"and":[49,115],"determined":[50],"these":[52],"were":[55,75,102,107,111],"causally":[56],"related":[57],"fluoxetine.":[59,86],"RESULTS:":[60],"In":[61],"reports":[62],"5,555":[67],"throughout":[71],"Zealand,":[73],"there":[74],"15":[76,98],"events":[80],"probably":[81],"or":[82,138,149],"possibly":[83],"caused":[84],"by":[85],"Fluoxetine":[87],"only":[90],"psychotropic":[91,147],"agent":[92],"used":[93],"for":[94],"seven":[95],"patients;":[99],"two":[100,110],"also":[103],"taking":[104,108,112,118],"lithium,":[105],"four":[106],"neuroleptics,":[109],"tricyclic":[113],"antidepressants,":[114],"one":[116],"metoclopramide.":[119],"CONCLUSIONS:":[120],"authors":[122],"conclude":[123],"may":[126,133,140],"be":[127],"reactions.":[131],"These":[132],"occur":[134],"alone":[137],"facilitate":[141],"reaction":[143],"receiving":[146],"medication":[148],"dopamine":[150],"receptor":[151],"blocking":[152],"drugs.":[153]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W28790285","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
